Successful treatment of ANCA-associated glomerulonephritis following pulmonary alveolar proteinosis by rituximab and avacopan

Rheumatology (Oxford). 2024 Feb 1;63(2):e51-e52. doi: 10.1093/rheumatology/kead421.

Authors

Masanari Sugawara¹, Arata Osanami², Yuichiro Asai³, Yayoi Ogawa⁴, Ken Nagahata¹, Hiroyuki Nakamura¹, Chisako Suzuki¹, Masatoshi Kanda¹, Hiroki Takahashi¹

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan.
² Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
³ Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sappro, Japan.
⁴ Hokkaido Renal Pathology Center, Sapporo, Japan.

PMID: 37603770
DOI: 10.1093/rheumatology/kead421

No abstract available

MeSH terms

Aniline Compounds*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*
Antibodies, Antineutrophil Cytoplasmic
Glomerulonephritis* / drug therapy
Humans
Nipecotic Acids*
Pulmonary Alveolar Proteinosis*
Rituximab / therapeutic use

Substances

Rituximab
Antibodies, Antineutrophil Cytoplasmic
avacopan
Aniline Compounds
Nipecotic Acids